Press Releases

IR Mobile SiteTear sheetEmail pagePDF viewPrint viewRSS FeedsEmail AlertSocial Media Sharing


Year:
Notify me when new press releases are posted to this site.
Press Releases
11/09/2004Cubist Pharmaceuticals Announces the Completion of Patient Enrollment in Cubicin's Phase 3 Endocarditis/Bacteremia Trial
10/27/2004Cubist Pharmaceuticals Reports Third-Quarter 2004 Results
10/26/2004Cubist Pharmaceuticals Announces Completion of the Fourth Safety Review of Endocarditis/Bacteremia Data for Cubicin by Data Monitoring Committee
10/25/2004Cubist Pharmaceuticals Announces a 35% CUBICIN Revenue Increase from Second Quarter 2004 Results
10/12/2004Cubist Pharmaceuticals Announces Participation in the FDA's Anti-Infective Drugs Advisory Committee Meeting to Discuss Bacteremia Due to Staphylococcus aureus
9/29/2004Cubist Pharmaceuticals Files $100 Million Shelf Registration
9/27/2004Cubist Pharmaceuticals to Host Investor Event; Presentation to be Webcast at 6:00 pm ET on September 30, 2004
8/05/2004Cubist Pharmaceuticals Reports Second-Quarter 2004 Results
8/04/2004Cubist Pharmaceuticals Announces Completion of Third Safety Review of Endocarditis/Bacteremia Data for Cubicin By DMC
6/16/2004Phase 3 Data on CUBICIN Published in Journal Clinical Infectious Diseases
6/07/2004Cubist Pharmaceuticals and Chiron Corporation Announce Plans to File for European Regulatory Approval of Cubicin --Daptomycin for Injection-- by Year-End 2004
6/03/2004Cubist Pharmaceuticals And XTL Biopharmaceuticals Complete License Agreement for Worldwide Rights to Hepatitis B Product
5/06/2004Cubist Pharmaceuticals Reports First-Quarter 2004 Results
4/29/2004Cubist Pharmaceuticals Announces Development Decision On OCTX Program
4/01/2004Cubist Pharmaceuticals Announces Completion of Second Safety Review of Endocarditis/Bacteremia Data for Cubicin by DMC; DMC Again Recommends Continuation of Trial
3/24/2004Cubist Pharmaceuticals Provides Update on CUBICIN Launch; Gives 2004 Revenue Guidance of $40-50 Million
3/17/2004Cubist Pharmaceuticals Launches CORE, a CUBICIN U.S. Clinical Outcomes Registry
3/15/2004Cubist Pharmaceuticals CEO Interviewed On CEOCast.com
2/26/2004Cubist Pharmaceuticals Reports Fourth-Quarter and Full-Year 2003 Results; Company Also Announces Discontinuation of CAB-175 Program; Conference Call & Webcast Today at 10:30 am ET
1/16/2004Cubist Provides Launch Update on Cubicin at 22nd Annual JP Morgan Healthcare Conference
 
 Source: SNL Financial LC 
Rows 301 through 320 of 408 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Copyright 2013, © SNL Financial LC  Terms of Use